Injectable Targeted Therapy Market Report 2026

The injectable targeted therapy market size has grown rapidly in recent years. It will grow from $64.22 billion in 2025 to $71.03 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing cancer incidence rates, advancements in monoclonal antibody development, growing adoption of biologic therapies, expansion of oncology treatment centers, increased clinical research activity in targeted drugs.

The injectable targeted therapy market size is expected to see rapid growth in the next few years. It will grow to $105.2 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing approvals of targeted injectable therapies, rising investments in personalized medicine, expansion of biologics manufacturing capacity, growing focus on immunotherapy development, increasing demand for precision treatment protocols. Major trends in the forecast period include increasing development of precision oncology injectables, rising adoption of antibody-based therapeutics, growing focus on targeted drug delivery systems, expansion of combination injectable therapies, enhanced emphasis on reduced off-target toxicity.

The rising demand for personalized medicine is anticipated to boost the injectable targeted therapy market in the years ahead. Personalized medicine is a medical strategy that customizes prevention, diagnosis, and treatment based on an individual's genetic makeup, environmental influences, and lifestyle habits. This surge in personalized medicine stems from breakthroughs in genomics, which provide a more profound insight into personal genetic differences and support highly accurate, targeted therapies that enhance patient results and cut down on ineffective trial-and-error approaches. Injectable targeted therapy supports personalized medicine by administering medications that precisely address a patient's specific molecular or genetic disease characteristics, boosting effectiveness while curbing adverse effects. For example, in February 2024, the Personalized Medicine Coalition - a US-based nonprofit - reported that the FDA greenlit 16 new personalized therapies for rare disease patients in 2023, compared to just six in 2022. Among these 2023 approvals were seven cancer treatments and three for various other diseases and conditions. Thus, the growing need for personalized medicine is fueling expansion in the injectable targeted therapy market.

Major companies in the injectable targeted therapy market are prioritizing innovative approaches like subcutaneous injections to boost drug delivery efficiency, improve patient adherence, and more precisely target disease mechanisms. Subcutaneous injection involves delivering medication into the fatty layer just below the skin's dermis, enabling gradual absorption into the bloodstream. For example, in August 2025, Eisai Co., Ltd., a Japanese pharmaceutical firm, collaborated with Biogen Inc., a U.S. biotechnology company, and secured FDA approval for LEQEMBI IQLIK, a therapy for early Alzheimer's disease. This once-weekly subcutaneous maintenance treatment, which patients can self-administer at home following initial intravenous dosing, slows cognitive decline by removing amyloid beta plaques and protofibrils - primary contributors to Alzheimer's advancement. The formulation shortens treatment duration, minimizes systemic side effects relative to IV infusions, and reduces reliance on infusion centers, providing more independence for patients and caregivers.

In September 2025, Novartis AG, a Switzerland-based pharmaceutical company, acquired Tourmaline Bio Inc. for an undisclosed sum. Through this acquisition, Novartis AG seeks to bolster and expand its cardiovascular portfolio by incorporating pacibekitug, an innovative anti-inflammatory treatment that targets IL-6 to tackle residual inflammatory risk in atherosclerotic cardiovascular disease, thereby leading the way in inflammation-focused cardiovascular therapies and tapping into a rapidly expanding market.

Major companies operating in the injectable targeted therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Eisai Co. Ltd., Genentech Inc., Beigene Ltd., Agenus Inc., Xilio Therapeutics Inc.

North America was the largest region in the injectable targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the injectable targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the injectable targeted therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the injectable targeted therapy market by increasing costs of imported biologic raw materials, specialized manufacturing equipment, sterile filling systems, and cold-chain logistics components. Pharmaceutical manufacturers in North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces higher production input costs. These tariffs are increasing therapy development and production expenses. At the same time, they are encouraging localized biologics manufacturing, regional supply chain diversification, and investments in domestic injectable production facilities.

The injectable targeted therapy market research report is one of a series of new reports that provides injectable targeted therapy market statistics, including injectable targeted therapy industry global market size, regional shares, competitors with a injectable targeted therapy market share, detailed injectable targeted therapy market segments, market trends and opportunities, and any further data you may need to thrive in the injectable targeted therapy industry. This injectable targeted therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Injectable targeted therapy uses medications delivered via injection to precisely attack specific proteins or cells driving a disease. It seeks to manage conditions like cancer more effectively, minimizing harm to healthy tissues in contrast to traditional treatments.

The primary categories of injectable targeted therapies include monoclonal antibodies, small molecules, immunotoxins, and additional types. Monoclonal antibodies are laboratory-created proteins engineered to attach precisely to specific proteins on affected cells. Their key mechanisms of action encompass precise blockade of signaling pathways, directed transport of cell-killing agents, and enhancement of immune responses. These treatments are typically delivered via intravenous, subcutaneous, or intramuscular routes. They find use in various areas like oncology, cardiometabolism, immunology, infectious diseases, neuroscience, ophthalmology, and more, benefiting end users such as hospitals, specialty clinics, and research labs.

The injectable targeted therapy market consists of sales of bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.